icon-folder.gif   Conference Reports for NATAP  
 
  ID Week
Oct 8-12 2014
Philadelphia
Back grey_arrow_rt.gif
 
 
 
Safety Profile of HIV-1 Attachment Inhibitor Prodrug
BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Analysis

 
 
  Reported by Jules Levin
IDWeek 2014
8-12 October 2014, Philadelphia, PA, USA
 
J Lalezari1, GH Latiff2, C Brinson3, J Echevarría4, S Treviño-Pérez5, JR Bogner6, D Stock7, SR Joshi7, GJ Hanna8, M Lataillade7, for the AI438011 study team 1Quest Clinical Research, San Francisco, CA, USA; 2Maxwell Clinic, Durban, South Africa; 3Central Texas Clinical Research, Austin, TX, USA; 4Hospital Nacional Cayetano Heredia, Lima, Peru; 5Mexico Centre for Clinical Research, Mexico City, Mexico; 6Hospital of the University of Munich, Munich, Germany; 7Bristol-Myers Squibb, Wallingford, CT, USA; 8Bristol-Myers Squibb, Princeton, NJ, USA
 
IDSA: HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis - (10/10/14) (BMS663068 vs Reyataz)

ID1.gif

ID2.gif

ID3.gif

ID4.gif

ID5.gif

ID6.gif

ID7.gif

ID8.gif

ID9.gif

ID10.gif

ID11.gif

ID12.gif

ID13.gif